Marta Sanchez-Carbayo

Summary

Country: Spain

Publications

  1. pmc A quantitative proteomic analysis uncovers the relevance of CUL3 in bladder cancer aggressiveness
    Laura Grau
    Tumor Markers Group, Spanish National Cancer Research Center, Madrid, Spain
    PLoS ONE 8:e53328. 2013
  2. pmc Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays
    A Aleman
    Tumor Markers Group, Molecular Pathology Program, Spanish National Cancer Center, Madrid, Spain
    Br J Cancer 98:466-73. 2008
  3. doi request reprint Discovery of cancer biomarkers using antibody arrays
    Marta Sanchez-Carbayo
    Group Leader Spanish National Cancer Research Center, Tumor Markers Group, 308A, Melchor Fernandez Almagro 3, E 28029 Madrid, Spain 34 91 7328053 34 91 224 6972
    Expert Opin Med Diagn 2:249-62. 2008
  4. pmc Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer
    Monica Castro
    Oncology Department, Instituto Angel H Roffo, Buenos Aires, Argentina
    J Transl Med 8:86. 2010
  5. doi request reprint Antibody array-based technologies for cancer protein profiling and functional proteomic analyses using serum and tissue specimens
    Marta Sanchez-Carbayo
    Tumor Markers Group, Spanish National Cancer Research Center, 310A, Melchor Fernandez Almagro 3, 28029, Madrid, Spain
    Tumour Biol 31:103-12. 2010
  6. ncbi request reprint Antibody arrays: technical considerations and clinical applications in cancer
    Marta Sanchez-Carbayo
    Tumor Markers Group, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
    Clin Chem 52:1651-9. 2006
  7. ncbi request reprint [Use of antibodies arrays in the study of bladder cancer]
    M Sanchez-Carbayo
    Grupo de Marcadores Tumorales, Centro Nacional de Investigaciones Oncologicas, Madrid
    Actas Urol Esp 31:1082-8. 2007
  8. pmc Genomic and proteomic profiles reveal the association of gelsolin to TP53 status and bladder cancer progression
    Marta Sanchez-Carbayo
    Tumor Markers Group, Spanish National Cancer Center, Madrid, Spain
    Am J Pathol 171:1650-8. 2007
  9. ncbi request reprint Molecular alterations associated with bladder cancer progression
    Marta Sanchez-Carbayo
    Tumor Markers Group, Spanish National Cancer Center, Madrid, Spain
    Semin Oncol 34:75-84. 2007
  10. doi request reprint Antibody microarrays as tools for biomarker discovery
    Marta Sanchez-Carbayo
    Tumor Markers Group, Spanish National Cancer Research Center, Madrid, Spain
    Methods Mol Biol 785:159-82. 2011

Collaborators

Detail Information

Publications43

  1. pmc A quantitative proteomic analysis uncovers the relevance of CUL3 in bladder cancer aggressiveness
    Laura Grau
    Tumor Markers Group, Spanish National Cancer Research Center, Madrid, Spain
    PLoS ONE 8:e53328. 2013
    ....
  2. pmc Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays
    A Aleman
    Tumor Markers Group, Molecular Pathology Program, Spanish National Cancer Center, Madrid, Spain
    Br J Cancer 98:466-73. 2008
    ..The association of SOX9 hypermethylation with tumour progression and clinical outcome suggests its relevant clinical implications at stratifying patients affected with bladder cancer...
  3. doi request reprint Discovery of cancer biomarkers using antibody arrays
    Marta Sanchez-Carbayo
    Group Leader Spanish National Cancer Research Center, Tumor Markers Group, 308A, Melchor Fernandez Almagro 3, E 28029 Madrid, Spain 34 91 7328053 34 91 224 6972
    Expert Opin Med Diagn 2:249-62. 2008
    ..However, the cancer biomarker candidates delivered so far using this technology are still at an early developmental phase, requiring validation with many specimens focusing on specific clinical end points...
  4. pmc Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer
    Monica Castro
    Oncology Department, Instituto Angel H Roffo, Buenos Aires, Argentina
    J Transl Med 8:86. 2010
    ..The objective of this study was to examine a multiplexed approach to assess the methylation of tumor suppressor genes as tumor stratification and clinical outcome prognostic biomarkers for lung cancer...
  5. doi request reprint Antibody array-based technologies for cancer protein profiling and functional proteomic analyses using serum and tissue specimens
    Marta Sanchez-Carbayo
    Tumor Markers Group, Spanish National Cancer Research Center, 310A, Melchor Fernandez Almagro 3, 28029, Madrid, Spain
    Tumour Biol 31:103-12. 2010
    ....
  6. ncbi request reprint Antibody arrays: technical considerations and clinical applications in cancer
    Marta Sanchez-Carbayo
    Tumor Markers Group, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
    Clin Chem 52:1651-9. 2006
    ..Furthermore, identification and validation of protein expression patterns, characteristic of cancer progression, and tumor subtypes may intervene and improve tailored therapies in the clinical management of cancer patients...
  7. ncbi request reprint [Use of antibodies arrays in the study of bladder cancer]
    M Sanchez-Carbayo
    Grupo de Marcadores Tumorales, Centro Nacional de Investigaciones Oncologicas, Madrid
    Actas Urol Esp 31:1082-8. 2007
    ..In the near future, they may allow establishing tailored therapies according to the aggresiveness of each specific tumor...
  8. pmc Genomic and proteomic profiles reveal the association of gelsolin to TP53 status and bladder cancer progression
    Marta Sanchez-Carbayo
    Tumor Markers Group, Spanish National Cancer Center, Madrid, Spain
    Am J Pathol 171:1650-8. 2007
    ..This study further reveals that TP53 mutations are frequent events in bladder cancer progression and identified gelsolin related to TP53 status, tumor staging, and clinical outcome by independent high-throughput strategies...
  9. ncbi request reprint Molecular alterations associated with bladder cancer progression
    Marta Sanchez-Carbayo
    Tumor Markers Group, Spanish National Cancer Center, Madrid, Spain
    Semin Oncol 34:75-84. 2007
    ..Integration of data generated from in-depth clinical evaluation, histologic tumor characteristics, and validated biomarkers could provide highly accurate, predictive tools for management of the bladder cancer patient...
  10. doi request reprint Antibody microarrays as tools for biomarker discovery
    Marta Sanchez-Carbayo
    Tumor Markers Group, Spanish National Cancer Research Center, Madrid, Spain
    Methods Mol Biol 785:159-82. 2011
    ....
  11. pmc KISS1 methylation and expression as tumor stratification biomarkers and clinical outcome prognosticators for bladder cancer patients
    Virginia Cebrian
    Tumor Markers Group, Molecular Pathology Program, Spanish National Cancer Center, Madrid, Spain
    Am J Pathol 179:540-6. 2011
    ....
  12. doi request reprint Polyamine-modulated factor-1 methylation predicts Bacillus Calmette-Guérin response in patients with high-grade non-muscle-invasive bladder carcinoma
    Miguel Alvarez-Múgica
    Tumor Markers Group, Molecular Pathology Program, Spanish National Cancer Center, Madrid, Spain
    Eur Urol 63:364-70. 2013
    ..Bacillus Calmette-Guérin (BCG) is a standard treatment to reduce tumor recurrence and delay progression of high-risk non-muscle-invasive (NMI) bladder tumors. However, it is not clear yet which patients are more likely to respond to BCG...
  13. ncbi request reprint Galectin-3 expression is associated with bladder cancer progression and clinical outcome
    Giacomo Canesin
    Tumor Markers Group, Molecular Pathology Program, Spanish National Cancer Center, Madrid, Spain
    Tumour Biol 31:277-85. 2010
    ..Urinary protein levels served to identify bladder cancer patients. These observations suggest a role for galectin-3 as a biomarker for bladder cancer diagnostics, staging, and outcome prognosis...
  14. doi request reprint Methylation of a novel panel of tumor suppressor genes in urine moves forward noninvasive diagnosis and prognosis of bladder cancer: a 2-center prospective study
    Rodrigo García-Baquero
    Tumor Markers Group, Molecular Pathology Program, Spanish National Cancer Center, Madrid, Spain Urology Department, Hospital Puerta del Mar, Cadiz, Spain
    J Urol 190:723-30. 2013
    ..We examined the diagnostic, stratification and prognostic biomarker roles in urine of the methylation of a novel panel of tumor suppressor genes in bladder cancer...
  15. doi request reprint KiSS-1 methylation and protein expression patterns contribute to diagnostic and prognostic assessments in tissue specimens for colorectal cancer
    Patricia Moya
    Tumor Markers Group, Molecular Pathology Program, Spanish National Cancer Center, Madrid, Spain
    Tumour Biol 34:471-9. 2013
    ..KiSS-1 was revealed epigenetically modified in colorectal cancer. The diagnostic and prognostic utility of KiSS-1 methylation and expression patterns suggests their assessment for the clinical management of colorectal cancer patients...
  16. ncbi request reprint Searching urinary tumor markers for bladder cancer using a two-dimensional differential gel electrophoresis (2D-DIGE) approach
    Esteban Orenes-Piñero
    Tumor Markers Group, Molecular Pathology Program, Spanish National Cancer Research Center, Madrid, Spain
    J Proteome Res 6:4440-8. 2007
    ..88)). Thus, the 2D-DIGE approach has identified Reg-1 as a biomarker for bladder cancer diagnostics, staging, and outcome prognosis...
  17. doi request reprint miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer
    Patricia Puerta-Gil
    Tumor Markers Group, Molecular Pathology Program, Spanish National Cancer Center, Madrid, Spain
    Am J Pathol 180:1808-15. 2012
    ..Thus, bladder tumors were characterized by changes in miRNA expression that could aid in tumor stratification and clinical outcome prognosis, and miRNAs were detected in urinary specimens for noninvasive diagnosis...
  18. doi request reprint Serum and tissue profiling in bladder cancer combining protein and tissue arrays
    Esteban Orenes-Piñero
    Tumor Markers Group, Spanish National Cancer Research Center, Madrid, Spain
    J Proteome Res 9:164-73. 2010
    ..Moreover, the protein expression patterns of dynamin and clusterin in bladder tumors were shown to adjunct for histopathologic staging and clinical outcome prognosis...
  19. doi request reprint Diagnostic and prognostic utility of methylation and protein expression patterns of myopodin in colon cancer
    Sergio Esteban
    Tumor Markers Group, 308A, Molecular Pathology Program, Spanish National Cancer Center, Melchor Fernandez Almagro 3, 28029, Madrid, Spain
    Tumour Biol 33:337-46. 2012
    ..The diagnostic and prognostic clinical utility of myopodin methylation and expression patterns suggest considering their assessment for the clinical management of colon cancer patients...
  20. pmc Identification of prefoldin amplification (1q23.3-q24.1) in bladder cancer using comparative genomic hybridization (CGH) arrays of urinary DNA
    Virginia Lopez
    Tumor Markers Group, Molecular Pathology Program, Spanish National Cancer Center, Melchor Fernandez Almagro 3, Madrid E 28029, Spain
    J Transl Med 11:182. 2013
    ..Array-CGH represents a comprehensive tool to discover genomic disease alterations that could potentially be applied to body fluids. In this report, we aimed at applying array-CGH to urinary samples to characterize bladder cancer...
  21. doi request reprint Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours
    Miriam Agundez
    Tumour Markers Group, Spanish National Cancer Research Centre, Madrid, Spain
    Eur Urol 60:131-40. 2011
    ..Bacillus Calmette-Guérin (BCG) is a standard treatment for reducing tumour recurrence and delaying progression of high-risk non-muscle-invasive bladder tumours. However, it is not clear yet which patients are more likely to respond to BCG...
  22. pmc Multiplexed methylation profiles of tumor suppressor genes in bladder cancer
    Maria José Cabello
    Tumor Markers Group, Molecular Pathology Program, Spanish National Cancer Center, Madrid, Spain
    J Mol Diagn 13:29-40. 2011
    ....
  23. pmc Differential protein expression profiling by iTRAQ-two-dimensional LC-MS/MS of human bladder cancer EJ138 cells transfected with the metastasis suppressor KiSS-1 gene
    Isabel Ruppen
    Tumor Markers Group, Spanish National Cancer Research Center, 28029 Madrid, Spain
    Mol Cell Proteomics 9:2276-91. 2010
    ....
  24. doi request reprint Hypermethylation in bladder cancer: biological pathways and translational applications
    Marta Sanchez-Carbayo
    Tumor Markers Group, 308A, Spanish National Cancer Research Center, Melchor Fernandez Almagro 3, E 28029, Madrid, Spain
    Tumour Biol 33:347-61. 2012
    ....
  25. ncbi request reprint Dissecting cancer serum protein profiles using antibody arrays
    Marta Sanchez-Carbayo
    Tumor Markers Group, Spanish National Cancer Center CN10, Madrid, Spain
    Methods Mol Biol 428:263-87. 2008
    ..Technical requirements such as lower sample volume, antibody concentration, format versatility, and high reproducibility support their increasing impact in cancer research...
  26. ncbi request reprint Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays
    Marta Sanchez-Carbayo
    Division of Molecular Pathology and Computational Biology Center Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 24:778-89. 2006
    ..Bladder cancer is a common malignancy characterized by a poor clinical outcome when tumors progress into invasive disease. We sought to define genetic signatures characteristic of aggressive clinical behavior in advanced bladder tumors...
  27. pmc Profiling bladder cancer using targeted antibody arrays
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Am J Pathol 168:93-103. 2006
    ....
  28. ncbi request reprint Identification of PMF1 methylation in association with bladder cancer progression
    Ainel Aleman
    Tumor Markers Group, Molecular Pathology Program, Spanish National Cancer Center, Madrid, Spain
    Clin Cancer Res 14:8236-43. 2008
    ..The polyamine modulated factor-1 (PMF-1) is involved in polyamine homeostasis. After identifying an enriched CpG island encompassing the PMF1 promoter, we aimed at evaluating the clinical relevance of PMF1 methylation in bladder cancer...
  29. doi request reprint Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer
    Miguel Alvarez-Múgica
    Molecular Pathology Program, Spanish National Cancer Center, Madrid, Spain
    J Urol 184:1507-13. 2010
    ..We evaluated the role of myopodin methylation as a clinical outcome prognosticator and predictive biomarker for the bacillus Calmette-Guerin response in patients with T1G3 bladder tumors...
  30. pmc Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays
    Ingrid Babel
    Centro de Investigaciones Biologicas Consejo Superior de Investigaciones Cientificas, Madrid, Spain
    Mol Cell Proteomics 8:2382-95. 2009
    ....
  31. ncbi request reprint Expression profiling of osteosarcoma cells transfected with MDR1 and NEO genes: regulation of cell adhesion, apoptosis, and tumor suppression-related genes
    Marta Sanchez-Carbayo
    Memorial Sloan Kettering Cancer Center, Albert Einstein College of Medicine, York, New York 10021, USA
    Lab Invest 83:507-17. 2003
    ..This study further elucidates the genetic events associated with MDR1 expression and identifies novel targets associated with multidrug resistance...
  32. pmc Gene discovery in bladder cancer progression using cDNA microarrays
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Pathol 163:505-16. 2003
    ..The present study has identified molecular biomarkers of potential clinical significance and critical molecular targets associated with bladder cancer progression...
  33. ncbi request reprint Recent advances in bladder cancer diagnostics
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Biochem 37:562-71. 2004
    ..This review summarizes the reports utilizing high-throughput microarrays in bladder cancer and the implications of these analyses in the diagnosis and clinical management of patients with bladder cancer...
  34. ncbi request reprint Comparison of gene expression profiles in laser-microdissected, nonembedded, and OCT-embedded tumor samples by oligonucleotide microarray analysis
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Clin Chem 49:2096-100. 2003
  35. pmc Tumor suppressor role of KiSS-1 in bladder cancer: loss of KiSS-1 expression is associated with bladder cancer progression and clinical outcome
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Pathol 162:609-17. 2003
    ..A potential tumor suppressor role in bladder cancer was revealed for KiSS-1. Moreover, it showed predictive value by identifying patients with poor outcome...
  36. ncbi request reprint Molecular profiling of tumor progression in head and neck cancer
    Thomas J Belbin
    Department of Pathology, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY 10461, USA
    Arch Otolaryngol Head Neck Surg 131:10-8. 2005
    ..To assess gene expression changes associated with tumor progression in patients with squamous cell carcinoma of the oral cavity...
  37. ncbi request reprint Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 62:6973-80. 2002
    ..However, it appears that deregulation of cell adhesion is a common event associated with tumor progression in uroepithelial neoplasms...
  38. ncbi request reprint A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:3215-20. 2007
    ..In this study, we aim to evaluate the SNP309 in bladder cancer and to link it to TP53 status...
  39. ncbi request reprint Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
    J Urol 176:919-26; discussion 926. 2006
    ..We assessed variability in the diagnostic performance of NMP22 for detecting recurrence and progression in patients with Ta, T1, and/or CIS transitional cell carcinoma of the bladder in a large international cohort...
  40. ncbi request reprint Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder
    Shahrokh F Shariat
    Department of Urology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    J Urol 173:1518-25. 2005
    ..We developed and validated nomograms that accurately predict disease recurrence and progression in patients with Ta, T1, or CIS transitional cell carcinoma (TCC) of the bladder using a large international cohort...
  41. ncbi request reprint Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder
    Pierre I Karakiewicz
    Department of Urology, University of Montreal, Montreal, Quebec, Canada
    BJU Int 97:997-1001. 2006
    ....
  42. doi request reprint Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma
    Georg C Hutterer
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada
    BJU Int 101:561-5. 2008
    ..To assess the value of nuclear matrix protein-22 (NMP22), compared with urinary cytology, in predicting the recurrence of bladder cancer that is not transitional cell carcinoma (non-TCC)...
  43. pmc Differential exoprotease activities confer tumor-specific serum peptidome patterns
    Josep Villanueva
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Invest 116:271-84. 2006
    ..Our findings also have important implications for future peptide biomarker discovery efforts...